The Consumer Healthcare Products Association released the following statement in response to the Trump Administration’s “Buy American” Executive Order (EO) for essential pharmaceuticals.
CHPA released the following statement in response to the CDC Viewpoints article titled, “Prevention of Unintentional Medication Overdose Among Children,” published in the Journal of the American Medical Association.
The Consumer Healthcare Products Association released the following statement in response to the U.S. Food and Drug Administration report to Congress on the current cannabidiol marketplace.
The results of nearly all recent observational studies of patients from around the world diagnosed with COVID-19 show no association between exposure to NSAIDs (including ibuprofen) and worsening clinical outcomes.
CHPA takes pride in the diverse consumer base our industry serves, and we support those who are raising their voices to advocate for a more just and equitable future for our nation.
CHPA is rebranding its identity for the first time in 20 years. The rebranding effort has resulted in a new logo, tagline, and brand narrative following the addition of consumer medical devices to its scope of representation.
CHPA, its educational foundation, and member companies are empowering consumers to practice responsible self-care, providing resources to help respond to this pandemic. We’re guided by these core principles.
